Home › Prostate Cancer › Ohio › Cleveland
Prostate Cancer clinical trials in Cleveland, OH
34 studies for Prostate Cancer are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RecruitingPhase 3
- MetroHealth Medical Center, Cleveland
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- University Hospitals Cleveland Medical Center, Cleveland
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RecruitingPhase 2
- MetroHealth Medical Center, Cleveland
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
RecruitingPhase 2
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Recruiting
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
RecruitingPhase 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
RecruitingPhase 3
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RecruitingPhase 1
- University Hospitals Cleveland Medical Center, Cleveland
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
RecruitingPhase 3
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 12 mi away
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · 22 mi away
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
RecruitingPhase 2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Investigation of Impact of AI on Prostate Cancer Workflow
Recruiting
- Cleveland Clinic Foundation, Cleveland
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Recruiting
- University Hospitals Cleveland, Cleveland
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RecruitingPhase 3
- Case Western Reserve University, Cleveland
- Louis Stokes Cleveland VA Medical Center, Cleveland
- MetroHealth Medical Center, Cleveland
- and 5 more
The Vanguard Study: Testing a New Way to Screen for Cancer
RecruitingHealthy volunteers welcome
- Louis Stokes Cleveland VA Medical Center, Cleveland
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
RecruitingPhase 3
- Research Site, Cleveland
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RecruitingPhase 2
- University Hospitals Cleveland Medical Center, Cleveland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Recruiting
- Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RecruitingPhase 3
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- and 5 more
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RecruitingObservational study
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
RecruitingPhase 1
- Cleveland Clinic Foundation, Cleveland
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
RecruitingPhase 4
- Cleveland Clinic Foundation, Cleveland
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
RecruitingPhase 1/2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
RecruitingObservational study
- University Hospitals Cleveland Medical Center, Cleveland
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
- Research Site, Cleveland
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Recruiting
- UH Cleveland Medical Center, Cleveland
Cleveland African American Prostate Cancer Project
RecruitingHealthy volunteers welcome
- Barbershops Local to Cleveland, Cleveland
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RecruitingPhase 2/3
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
Recruiting
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
RecruitingObservational studyHealthy volunteers welcome
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi away
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RecruitingPhase 3
- MetroHealth Medical Center, Cleveland
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #7, Cleveland
About Prostate Cancer
Prostate cancer is one of the most common types of cancer among American men. The risk goes up as men age. Learn about symptoms, tests, and treatment.
More about Prostate Cancer on MedlinePlus
Prostate Cancer trials in other cities
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA59 studies
- St. Louis, MO46 studies
- Chicago, IL45 studies
- San Francisco, CA45 studies
- Philadelphia, PA44 studies
- Baltimore, MD43 studies
- Nashville, TN42 studies
- Seattle, WA42 studies
- Washington, DC38 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer30 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
- Crohn's Disease19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.